Predicted 5-Year DFS Estimates (%) by T stage, Nodal Status, and Grade for Patients Treated With Surgery Alone and Surgery With FU-Based Adjuvant Chemotherapy
A pooled analysis of adjuvant chemotherapy trials for patients with resected colon cancer was performed to quantify the benefit of 5FU-based chemotherapy for predefined clinical and pathologic subgroups. The table below provides individualised estimates of baseline prognosis and adjuvant-therapy benefit based on T stage, nodal status and grade.
Results are presented as % patients still alive at 5 years with 95% confidence interval and group size.
Low grade patients
Group |
Surgery Alone |
Surgery + Chemotherapy |
Abs. gain (%) |
|---|---|---|---|
0 nodes & T1-2 |
N/A |
N/A |
|
0 nodes & T3 |
73 - [69 - 76] |
77 - [74 - 80] |
4 |
0 nodes & T4 |
60 - [54 - 68] |
66 - [59 - 73] |
6 |
1-4 nodes & T1-2 |
62 - [56 - 70] |
75 - [70 - 81] |
13 |
1-4 nodes & T3 |
49 - [45 - 54] |
65 - [62 - 69] |
16 |
1-4 nodes & T4 |
33 - [26 - 43] |
51 - [44 - 60] |
18 |
5+ nodes & T1-2 |
39 - [30 - 51] |
57 - [48 - 67] |
18 |
5+ nodes & T3 |
24 - [19 - 31] |
43 - [37 - 49] |
19 |
5+ nodes & T4 |
11 - [6 - 20] |
27 - [19 - 37] |
16 |
High grade patients
Group |
Surgery Alone |
Surgery + Chemotherapy |
Abs. gain (%) |
|---|---|---|---|
0 nodes & T1-2 |
N/A |
N/A |
|
0 nodes & T3 |
65 - [60 - 70] |
70 - [65 - 74] |
5 |
0 nodes & T4 |
51 - [43 - 60] |
57 - [49 - 66] |
6 |
1-4 nodes & T1-2 |
53 - [44 - 63] |
68 - [61 - 76] |
15 |
1-4 nodes & T3 |
38 - [33 - 44] |
56 - [51 - 62] |
18 |
1-4 nodes & T4 |
23 - [16 - 32] |
40 - [32 - 51] |
17 |
5+ nodes & T1-2 |
28 - [19 - 42] |
46 - [37 - 58] |
18 |
5+ nodes & T3 |
15 - [10 - 22] |
32 - [26 - 39] |
17 |
5+ nodes & T4 |
5 - [3 - 12] |
17 - [11 - 26] |
12 |
Abbreviations
- DFS: disease-free survival
- 5-FU: 5-fluorouracil
- N/A: not applicable (because of insufficient clinical data for resected T1 to T2, N0 or stage I colon cancer)
Reprinted with permission. ©2008 American Society of Clinical Oncology. All rights reserved. Gill S et al: Pooled Analysis of Fluorouracil-Based Adjuvant Therapy for Stage II and III Colon Cancer: Who Benefits and by How Much? J Clin Oncol Vol.22 (10), 2004: 1797-1806.